Figure 4
Spectrum and distribution of SDH germ-line mutations exclusively identified in gastrointestinal stromal tumors (GISTs), renal-cell carcinomas (RCCs), or pituitary adenomas (PAs) and as reported in tumors occurring rarely in the context of SDH deficiency. (a) Spectrum and distribution of SDH mutations exclusively identified in GISTs, RCCs, and PAs: percentages of mutations as reported only in GISTs, RCCs, and PAs in each of those tumor types (A.1); percentages of the mutations reported in the related tumor types except pheochromocytomas (PCCs)/paragangliomas (PGLs) in each SDH gene and of the different types of mutations (A.2); and percentages of the different mutation types identified in the related tumor types except PCCs/PGLs for each SDH gene (A.3). (b) Spectrum and distribution of SDH mutations as reported in tumors occurring rarely in the context of SDH deficiency: percentages of mutations in each SDH gene and of the different types of mutations reported in different tumors including thyroid carcinomas and neuroblastomas (B.1), and percentages of different mutation types identified in these different tumors for each SDH gene (B.2).
